Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours

Información del proyecto

Tumor-Treg-Targeting

Identificador del acuerdo de subvención: 765394

DOI

10.3030/765394

Proyecto cerrado

Fecha de la firma de la CE 2 Agosto 2017

Fecha de inicio 1 Junio 2018

Fecha de finalización 30 Noviembre 2022

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 1 273 933,58

Aportación de la UE

€ 1 273 933,58

Coordinado por

UNIVERSIDAD DE NAVARRA
Spain

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Documents, reports (2)

ESR research outputs (publications, patent applications and presentations at conferences) and products)

Report that will compile relevant information concerning the research outputs publications done patent applications obtained presentations carried out at conferences and products achieved by each ESR

Dissemination of Tumor Treg Taregting results and achievements to the Scientific Community and products

This report will compile all the actions urdertaken by project partners to disseminate at national and international levels the project results and achievements to the Scientific Community and Wider Public

Other (3)

Completion of PhD Thesis and award of Doctoral Degrees

Completion of PhD Thesis and award of Doctoral Degrees: 5 PhD Thesis are expected. After thirty-six months each ESR will submitt his/her thesis which will be evaluated by the supervisors, the local GSC, and an external reviewer. The thesis is then defended in an oral examination (viva voce).

ESR organised workshop on antibody mediated tumour therapy

During the last network meeting (month 45 in Utrecht/NL) ESR-organized School on antibody-based tumour therapy will be held. This international meeting (3-5 days) will be organized by the ESRs. This meeting will be open to a general, interested public and other scientists outside of the network. This conference will include invited international speakers chosen and invited by the ESRs. Speakers and poster presentations will further be selected from abstracts, submitted by participants. Thus this meeting will allow the network to report their findings and advances to the scientific community, and ESRs to further plan their scientific careers. To fully organize such a School will allow the students to be further trained in organizing conferences, attracting funding/sponsoring from companies and in networking with world-leading scientists. It is the intention that such a School will be continued even after the completion of this project, fostering European networking in this area.

"4-day business course (""learning by simulation"")"

A 4-day business course (biologicals simulation course) will be developed to train Ph.D. level scientists in biopharmaceutical drug discovery and development, available through LBS (www.learningbysimulation.com). LBS will specifically set up one of their courses for the 5 ESRs of this training network.

Websites, patent fillings, videos etc. (1)

Launch and management of the Tumor Treg Targerting website

General audience will be reached via the establishment of a project specific web-site. The web-site will make reference to the aims, the background of the project, and general as well as specific advances in the field of cancer therapy. Specific breakthrough achievements of the ESR's projects will be posted, which will regularly be updated with PDFs of publications, made available by 6 months post publication or earlier. Any press article and review articles will be available for download or upon request. ESRs will use the website to disseminate their projects. They will place short videos explaining in easily understable, non specialist language, their projects and further implications for the wider society. In addition, the web-site will be used to advertise the job offers during the recruitment period. The website will also contain special area for social media with the information that will appear on the project twitter, facebook, linkedin and Youtube.

Publicaciones

Peer reviewed articles (18)

Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice

Autores: Ardaiz N, Gomar C, Vasquez M, Tenesaca S, Fernandez-Sendin M, Di Trani CA, Belsué V, Escalada J, Werner U, Tennagels N, Berraondo P.
Publicado en: Front Pharmacol., 2021, ISSN 1663-9812
Editor: Frontiers Media S.A.
DOI: 10.3389/fphar.2020.591293

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis

Autores: Bella Á, Arrizabalaga L, Di Trani CA, Cirella A, Fernandez-Sendin M, Gomar C, Russo-Cabrera JS, Rodríguez I, González-Gomariz J, Alvarez M, Teijeira Á, Medina-Echeverz J, Hinterberger M, Hochrein H, Melero I, Berraondo P, Aranda F.
Publicado en: Oncoimmunology, 2022, ISSN 2162-4011
Editor: Landes Bioscience
DOI: 10.1080/2162402x.2022.2098657

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.

Autores: Huang, Shuyu; van Duijnhoven, Sander M J; Sijts, Alice J A M; van Elsas, Andrea; Immunologie; dI&I RA-I&I I&I
Publicado en: Journal of Cancer Research and Clinical Oncology, Edición 5, 2020, ISSN 0171-5216
Editor: Springer Verlag
DOI: 10.1007/s00432-020-03404-6

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Autores: Teijeira A, Migueliz I, Garasa S, Karanikas V, Luri C, Cirella A, Olivera I, Cañamero M, Alvarez M, Ochoa MC, Rouzaut A, Rodriguez-Ruiz ME, Sanmamed MF, Klein C, Umaña P, Ponz M, Bacac M, Melero I.
Publicado en: Theranostics, 2022, ISSN 1838-7640
Editor: Ivyspring International Publisher
DOI: 10.7150/thno.63359

Isotype selection for antibody‐based cancer therapy

Autores: N. Vukovic, A. Elsas, J. S. Verbeek, D. M. W. Zaiss
Publicado en: Clinical & Experimental Immunology, Edición 203/3, 2021, Página(s) 351-365, ISSN 0009-9104
Editor: Blackwell Publishing Inc.
DOI: 10.1111/cei.13545

INTERLEUKIN-12 MESSAGE IN A BOTTLE

Autores: Cirella, A. Berraondo, P. Di-Trani, C.A. Melero, I.
Publicado en: Clin Cancer Res, 2020, ISSN 1078-0432
Editor: American Association for Cancer Research
DOI: 10.1158/1078-0432.ccr-20-3250

Mouse IgG2a Isotype Therapeutic Antibodies Elicit Superior Tumor Growth Control Compared with mIgG1 or mIgE

Autores: Vukovic N, Segués A, Huang S, Waterfall M, Sijts AJAM, Zaiss DM.
Publicado en: Cancer Res Commun, 2023, ISSN 2767-9764
Editor: American Association for Cancer Research
DOI: 10.1158/2767-9764.crc-22-0356

Novel strategies exploiting interleukin-12 in cancer immunotherapy

Autores: Cirella A, Luri-Rey C, Di Trani CA, Teijeira A, Olivera I, Bolaños E, Castañón E, Palencia B, Brocco D, Fernández-Sendin M, Aranda F, Berraondo P, Melero I. Novel strategies exploiting interleukin-12 in cancer immunotherapy
Publicado en: Pharmacology & Therapeutics, 2022, ISSN 0163-7258
Editor: Pergamon Press
DOI: 10.1016/j.pharmthera.2022.108189

Advances in mRNA-based drug discovery in cancer immunotherapy.

Autores: Di Trani CA, Fernandez-Sendin M, Cirella A, Segués A, Olivera I, Bolaños E, Melero I, Berraondo P.
Publicado en: Expert Opin Drug Discov., 2022, ISSN 1746-0441
Editor: Informa Healthcare
DOI: 10.1080/17460441.2021.1978972

A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing

Autores: Shuyu Huang, Aina Segués, David Lutje Hulsik, Dietmar M. Zaiss, Alice J.A.M. Sijts, Sander M.J. van Duijnhoven, Andrea van Elsas
Publicado en: Journal of Immunological Methods, Edición 483, 2020, Página(s) 112811, ISSN 0022-1759
Editor: Elsevier BV
DOI: 10.1016/j.jim.2020.112811

Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications

Autores: Angela Bella; Claudia Augusta Di Trani; Myriam Fernandez-Sendin; Leire Arrizabalaga; Assunta Cirella; Alvaro Teijeira; José Medina-Echeverz; Ignacio Melero; Pedro Berraondo; Fernando Aranda
Publicado en: Cancers, Edición 3, 2021, ISSN 2072-6694
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers13050963

Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors

Autores: Shirley Tenesaca; Marcos Vasquez; Maite Alvarez; Itziar Otano; Myriam Fernandez-Sendin; Claudia Augusta Di Trani; Nuria Ardaiz; Celia Gomar; Angela Bella; Fernando Aranda; José Medina-Echeverz; Ignacio Melero; Pedro Berraondo
Publicado en: Journal for Immunotherapy of Cancer, Edición 1, 2021, ISSN 2051-1426
Editor: BMJ publishing group
DOI: 10.1136/jitc-2020-001587

Long-Term Liver Expression of an Apolipoprotein A-I Mimetic Peptide Attenuates Interferon-Alpha-Induced Inflammation and Promotes Antiviral Activity

Autores: Fernandez-Sendin M, Di Trani CA, Bella A, Vasquez M, Ardaiz N, Gomar C, Arrizabalaga L, Ciordia S, Corrales FJ, Aranda F, Berraondo P.
Publicado en: Frontiers in immunology, 2021, ISSN 1664-3224
Editor: Lausanne: Frontiers Media S.A., 2010-
DOI: 10.3389/fimmu.2020.620283

Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils

Autores: Teijeira A, Garasa S, Ochoa MDC, Cirella A, Olivera I, Glez-Vaz J, Andueza MP, Migueliz I, Alvarez M, Rodríguez-Ruiz ME, Rouzaut A, Berraondo P, Sanmamed MF, Perez Gracia JL, Melero I
Publicado en: Eur J Immunol, 2021, ISSN 0014-2980
Editor: John Wiley & Sons Ltd.
DOI: 10.1002/eji.202049029

Purification of murine immunoglobulin E (IgE) by thiophilic interaction chromatography (TIC)

Autores: Natasa Vukovic, Salim Harraou, Sander M.J. van Duijnhoven, Dietmar M. Zaiss, Andrea van Elsas
Publicado en: Journal of Immunological Methods, Edición 489, 2021, Página(s) 112914, ISSN 0022-1759
Editor: Elsevier BV
DOI: 10.1016/j.jim.2020.112914

A Human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes

Autores: Vukovic, Natasa; Halabi, Samer; Russo-Cabrera, Joan Salvador; Blokhuis, Bart; Berraondo, Pedro; Redegeld, Frank A M; Zaiss, Dietmar M W; Afd Pharmacology; LS Immunologie; Pharmacology
Publicado en: VOLUME=298;ISSUE=8;STARTPAGE=1;ISSN=0021-9258;TITLE=Journal of Biological Chemistry, Edición 7, 2022, ISSN 0021-9258
Editor: American Society for Biochemistry and Molecular Biology Inc.
DOI: 10.1016/j.jbc.2022.102153

Shortened hinge design of Fab x sdAb-Fc bispecific antibodies enhances redirected T-Cell killing of tumor cells

Autores: Shuyu Huang; Aina Segués; Martin Waterfall; David Wright; Charlotte Vayssiere; Sander M. J. van Duijnhoven; Andrea van Elsas; Alice J. A. M. Sijts; Dietmar M. Zaiss
Publicado en: Biomolecules; Volume 12; Edición 10; Pages: 1331, Edición 1, 2020, ISSN 0171-5216
Editor: Springer Verlag
DOI: 10.3390/biom12101331

Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies

Autores: Aina Segués, Sander M.J. van Duijnhoven, Marc Parade, Lilian Driessen, Nataša Vukovic, Dietmar Zaiss, Alice J.A.M. Sijts, Pedro Berraondo, Andrea van Elsas
Publicado en: Journal of Immunological Methods, Edición 499, 2021, Página(s) 113173, ISSN 0022-1759
Editor: Elsevier BV
DOI: 10.1016/j.jim.2021.113173

Book chapters (1)

Opportunities and challenges of bi-specific antibodies

Autores: Segués A, Huang S, Sijts A, Berraondo P, Zaiss DM
Publicado en: Int Rev Cell Mol Biol, 2022, ISSN 1937-6448
Editor: Elsevier Inc.
DOI: 10.1016/bs.ircmb.2022.05.001